Cabazitaxel in Metastatic Prostate Cancer

To the Editor: In the CARD trial reported by de Wit et al. (Dec. 26 issue),(1) 255 patients with metastatic castration-resistant prostate cancer who had previously received docetaxel and who had disease progression while receiving abiraterone or enzalutamide were randomly assigned to cabazitaxel or the other androgen-signaling-targeted inhibitor. Cabazitaxel significantly improved several clinical outcomes, including imaging-based progression-free survival and overall survival, as compared with hormonal treatment. This trial represents an important step forward in the understanding of appropriate advanced treatment in patients with metastatic castration-resistant prostate cancer. However, it should be noted that 61.2% of the patients received hormonal treatment . . .